NASDAQ · RLAY
Relay Therapeutics, Inc.
$18.40-$1.07 (-5.5%)
Relay Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.5% below the high.
Loading market information…
NASDAQ · TERN · USD
Stock price, earnings
Quote as of May 15, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Terns Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.45% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Terns Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:35 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2024 |
|---|
| Aug 5, 2024 |
| -$0.31+11.43% vs estimate |
| $0.00 |
THE ANALYST VIEW
16 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$18.40-$1.07 (-5.5%)
Relay Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.5% below the high.
$28.76+$0.08 (+0.28%)
Amylyx Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 30.09% below the high.
$44.91-$0.18 (-0.39%)
Enliven Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 27.94% below the high.
$6.68+$0.04 (+0.57%)
Precigen, Inc.’s quoted price sits in the upper half of its reported 52-week range, 25.64% below the high.
$47.98$0.00 (0.0%)
Tourmaline Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.6% below the high.
$13.74-$0.41 (-2.9%)
Syndax Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.31% below the high.
$38.44-$0.74 (-1.89%)
Nektar Therapeutics’s quoted price sits in the lower half of its reported 52-week range, 64.73% below the high.
$6.90-$0.41 (-5.61%)
Immatics N.V.’s quoted price sits in the lower half of its reported 52-week range, 44.4% below the high.
